公开(公告)号：US11629188B2

公开(公告)日：2023-04-18

申请号：US16803972

申请日：2020-02-27

申请人： ONCOC4, INC.

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00

摘要： This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US11261233B2

公开(公告)日：2022-03-01

申请号：US16333888

申请日：2017-09-19

申请人： ONCOC4, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Wei Wu ,  Xuexiang Du ,  Mingyue Liu ,  Fei Tang

IPC分类号： C07K14/705 ,  C07K16/46 ,  A61K38/00 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  C07K14/00 ,  A61K39/00

摘要： This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

公开(公告)号：US12129299B2

公开(公告)日：2024-10-29

申请号：US16967079

申请日：2019-01-29

申请人： ONCOC4, INC. ,  University of Maryland, Baltimore

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  C07K16/2827 ,  C07K2317/565 ,  C07K2317/71

摘要： This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20240139280A1

公开(公告)日：2024-05-02

申请号：US18286334

申请日：2022-04-13

申请人： ONCOC4, INC. ,  University of Maryland, Baltimore

发明人： Yin Wang ,  Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Yan Liu ,  Christopher Bailey

IPC分类号： A61K38/12 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K38/12 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

摘要： The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.